Commercial Sales Launch Following FDA Approval; National Sales Force Now in Action as January Shipments and Major Market Opportunity Take Shape
NRx Pharmaceuticals (NRXP) began commercial sales of its FDA-approved preservative-free ketamine, with a 17-person sales team targeting 80% of U.S. ketamine sales. The company expects over 50% gross and net margins, with shipments starting in January 2027. NRx is also expanding its manufacturing capacity and has a $11.25M DARPA contract for depression treatment research.
How this was made

The 30-second read
Why it matters
The commercial launch provides a tangible revenue catalyst and showcases a scalable manufacturing process that could be applied to other injectables.
Market read
The announcement introduces a new product line with high‑margin potential, likely influencing biotech and specialty pharma sentiment.
What to watch
Potential reimbursement challenges and competition from existing ketamine products may temper revenue growth.
Background
NRx Pharmaceuticals recently received FDA approval for a preservative‑free ketamine formulation and is now moving into commercial sales.
Ticker impact
NRx Pharmaceuticals announced the start of commercial sales for its FDA‑approved preservative‑free ketamine and activated a 17‑person national sales force.
likely upward pressure as investors price in the commercial rollout and high‑margin expectations
First‑report of FDA approval and immediate sales activation for a niche injectable drug; management cites strong margin potential and a scalable manufacturing platform.
Market effects
May boost sentiment for specialty pharma and injectable drug manufacturers that rely on niche formulations.
U.S. healthcare procurement market sees a new domestic source for ketamine, potentially reducing reliance on imported products.
Limited to U.S. market but could attract interest from global investors tracking niche biotech launches.
Counterpoint
If demand for ketamine remains limited or pricing pressures intensify, the high‑margin outlook could be overstated.
Key entities
- companyNRx Pharmaceuticals, Inc.
NASDAQ‑listed biotech launching preservative‑free ketamine.
- government_agencyDARPA
Awarded an $11.25 million contract to NRx for a brain‑stimulation research program.

